Last reviewed · How we verify

Buserelin and Pregnyl

Regionshospitalet Viborg, Skive · FDA-approved active Small molecule Quality 5/100

Buserelin and Pregnyl is a Small molecule drug developed by Regionshospitalet Viborg, Skive. It is currently FDA-approved.

At a glance

Generic nameBuserelin and Pregnyl
SponsorRegionshospitalet Viborg, Skive
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Buserelin and Pregnyl

What is Buserelin and Pregnyl?

Buserelin and Pregnyl is a Small molecule drug developed by Regionshospitalet Viborg, Skive.

Who makes Buserelin and Pregnyl?

Buserelin and Pregnyl is developed and marketed by Regionshospitalet Viborg, Skive (see full Regionshospitalet Viborg, Skive pipeline at /company/regionshospitalet-viborg-skive).

What development phase is Buserelin and Pregnyl in?

Buserelin and Pregnyl is FDA-approved (marketed).

Related